Journal Article Summary
The article investigates the effectiveness of a combination treatment involving 6-thioguanine, capecitabine, and celecoxib alongside either temozolomide or lomustine for patients with recurrent high-grade gliomas, specifically glioblastoma and anaplastic glioma. This research is significant as gliomas are aggressive brain tumors with limited treatment options and poor survival rates. The study aims to explore whether this new combination therapy can improve progression-free survival (PFS) and overall survival compared to existing treatments.
In this study, 74 patients were enrolled, including 43 with glioblastoma and 31 with anaplastic glioma. The patients received either temozolomide or lomustine, along with the other three drugs. The results showed that for glioblastoma patients, the objective response rate was 12%, with a 6-month PFS of 14% and a median overall survival of 32 weeks. In contrast, patients with anaplastic glioma had a more favorable outcome, with a 12-month PFS of 44% and a 26% objective response rate.
The study has limitations, including a small sample size and the early closure of the anaplastic glioma group due to slow patient enrollment, which may affect the reliability of the findings. While the treatment was generally well tolerated, with common but manageable side effects, patients should discuss any new treatment options with their healthcare providers. It is essential for patients to consider the potential risks and benefits of this combination therapy, especially since it did not show significant improvement for glioblastoma compared to existing treatments, although it may hold promise for anaplastic glioma patients.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Walbert Tobias, Gilbert Mark R., Groves Morris D., Puduvalli Vinay K., Alfred Yung W. K., Conrad Charles A., Bobustuc George C., Colman Howard, et al.. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. Journal of neuro-oncology 2010. DOI: 10.1007/s11060-010-0313-7. PMID: 20652724. PMCID: PMC5557017.
Featured Pill Pals Product
Celecoxib 100 mg Capsules --- Generic For Celebrex --- Mullan
Celecoxib 100 mg Capsules — Generic For Celebrex — Mullan is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
